FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894772004> ?p ?o ?g. }

• W2894772004 endingPage "34809" @default.
• W2894772004 startingPage "34794" @default.
• W2894772004 abstract "// Alexandra Samsen 1 , Silvia von der Heyde 2 , Carsten Bokemeyer 3 , Kerstin A. David 2 , Bernd Flath 4 , Max Graap 1 , Bianca Grebenstein 1 , Ludger Heflik 5 , Wiebke Hollburg 4 , Peter Layer 6 , Eike von Leitner 1 , Friedrich Overkamp 7 , Wolfgang Saeger 1 , Sandra Schneider 1 , Cay-Uwe von Seydewitz 8 , Axel Stang 9 , Alexander Stein 3 , Carsten Zornig 6 and Hartmut Juhl 1 1 IndivuTest GmbH, Hamburg, Germany 2 Indivumed GmbH, Hamburg, Germany 3 II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, Bone Marrow Transplantation and Pneumology, University Cancer Center Hamburg, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 4 HOPA-Hämatologisch−Onkologische Praxis Altona, Hamburg, Germany 5 Praxis Und Tagesklinik Für Internistische Onkologie und Hämatologie, Recklinghausen, Germany 6 Israelitisches Krankenhaus, Hamburg, Germany 7 Oncologianova GmbH, Recklinghausen, Germany 8 Medizinische Klinik, Onkologie/Hämatologie Und Palliativmedizin, Krankenhaus Reinbek St Adolf-Stift, Reinbek, Germany 9 Department of Hematology, Oncology and Palliative Medicine, Asklepios Klinik Barmbek, Hamburg, Germany Correspondence to: Alexandra Samsen, email: samsen@indivutest.com Keywords: molecular profiling; advanced stage IV cancer; MAPK pathway; PI3K/AKT/mTOR pathway; targeted therapy Received: August 03, 2018      Accepted: September 10, 2018      Published: October 05, 2018 ABSTRACT A proof-of-concept study was conducted to assess whether patients with advanced stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Expression and phosphorylation of key oncogenic pathways were measured to identify targets at the (phospho-) proteomic level. At genomic level, 50 oncogenes and tumor suppressor genes were analyzed. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell in two equal-sized groups. One group received targeted therapies while the other did not. Following six months of treatment, disease control was achieved by 49% of patients receiving targeted therapy (complete remission, 14%; partial remission, 21%; stable disease, 14%; disease progression, 36%; death, 14%) and 21% of patients receiving non-targeted therapy (stable disease, 21%; disease progression, 64%; death, 14%). Individual patients experienced dramatic responses to a therapy which otherwise would not have been applied. This approach clarifies the value of multi-omic molecular profiling for cancer diagnostics." @default.
• W2894772004 created "2018-10-12" @default.
• W2894772004 creator A5000809939 @default.
• W2894772004 creator A5017141631 @default.
• W2894772004 creator A5019870592 @default.
• W2894772004 creator A5021910799 @default.
• W2894772004 creator A5022161970 @default.
• W2894772004 creator A5023472696 @default.
• W2894772004 creator A5030150914 @default.
• W2894772004 creator A5033733526 @default.
• W2894772004 creator A5040979889 @default.
• W2894772004 creator A5044160974 @default.
• W2894772004 creator A5051887011 @default.
• W2894772004 creator A5052118312 @default.
• W2894772004 creator A5053310450 @default.
• W2894772004 creator A5053845865 @default.
• W2894772004 creator A5078383767 @default.
• W2894772004 creator A5083294282 @default.
• W2894772004 creator A5084086757 @default.
• W2894772004 creator A5088354106 @default.
• W2894772004 creator A5088860959 @default.
• W2894772004 date "2018-10-05" @default.
• W2894772004 modified "2023-09-27" @default.
• W2894772004 title "Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients" @default.
• W2894772004 cites W1550092206 @default.
• W2894772004 cites W1570622790 @default.
• W2894772004 cites W1580924836 @default.
• W2894772004 cites W1840179701 @default.
• W2894772004 cites W1979405808 @default.
• W2894772004 cites W1998203489 @default.
• W2894772004 cites W2016966976 @default.
• W2894772004 cites W2032242790 @default.
• W2894772004 cites W2045766910 @default.
• W2894772004 cites W2058657848 @default.
• W2894772004 cites W2062550680 @default.
• W2894772004 cites W2078276694 @default.
• W2894772004 cites W2103808574 @default.
• W2894772004 cites W2104287359 @default.
• W2894772004 cites W2111578514 @default.
• W2894772004 cites W2120627364 @default.
• W2894772004 cites W2128307445 @default.
• W2894772004 cites W2133296598 @default.
• W2894772004 cites W2141285914 @default.
• W2894772004 cites W2148527073 @default.
• W2894772004 cites W2156251761 @default.
• W2894772004 cites W2161375781 @default.
• W2894772004 cites W2167121370 @default.
• W2894772004 cites W2170049466 @default.
• W2894772004 cites W2197170290 @default.
• W2894772004 cites W2580868502 @default.
• W2894772004 cites W2586217845 @default.
• W2894772004 cites W2802022482 @default.
• W2894772004 doi "https://doi.org/10.18632/oncotarget.26198" @default.
• W2894772004 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6205171" @default.
• W2894772004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410678" @default.
• W2894772004 hasPublicationYear "2018" @default.
• W2894772004 type Work @default.
• W2894772004 sameAs 2894772004 @default.
• W2894772004 citedByCount "3" @default.
• W2894772004 countsByYear W28947720042019 @default.
• W2894772004 countsByYear W28947720042021 @default.
• W2894772004 crossrefType "journal-article" @default.
• W2894772004 hasAuthorship W2894772004A5000809939 @default.
• W2894772004 hasAuthorship W2894772004A5017141631 @default.
• W2894772004 hasAuthorship W2894772004A5019870592 @default.
• W2894772004 hasAuthorship W2894772004A5021910799 @default.
• W2894772004 hasAuthorship W2894772004A5022161970 @default.
• W2894772004 hasAuthorship W2894772004A5023472696 @default.
• W2894772004 hasAuthorship W2894772004A5030150914 @default.
• W2894772004 hasAuthorship W2894772004A5033733526 @default.
• W2894772004 hasAuthorship W2894772004A5040979889 @default.
• W2894772004 hasAuthorship W2894772004A5044160974 @default.
• W2894772004 hasAuthorship W2894772004A5051887011 @default.
• W2894772004 hasAuthorship W2894772004A5052118312 @default.
• W2894772004 hasAuthorship W2894772004A5053310450 @default.
• W2894772004 hasAuthorship W2894772004A5053845865 @default.
• W2894772004 hasAuthorship W2894772004A5078383767 @default.
• W2894772004 hasAuthorship W2894772004A5083294282 @default.
• W2894772004 hasAuthorship W2894772004A5084086757 @default.
• W2894772004 hasAuthorship W2894772004A5088354106 @default.
• W2894772004 hasAuthorship W2894772004A5088860959 @default.
• W2894772004 hasBestOaLocation W28947720041 @default.
• W2894772004 hasConcept C121608353 @default.
• W2894772004 hasConcept C126322002 @default.
• W2894772004 hasConcept C143998085 @default.
• W2894772004 hasConcept C71924100 @default.
• W2894772004 hasConceptScore W2894772004C121608353 @default.
• W2894772004 hasConceptScore W2894772004C126322002 @default.
• W2894772004 hasConceptScore W2894772004C143998085 @default.
• W2894772004 hasConceptScore W2894772004C71924100 @default.
• W2894772004 hasIssue "78" @default.
• W2894772004 hasLocation W28947720041 @default.
• W2894772004 hasLocation W28947720042 @default.
• W2894772004 hasLocation W28947720043 @default.
• W2894772004 hasLocation W28947720044 @default.
• W2894772004 hasOpenAccess W2894772004 @default.
• W2894772004 hasPrimaryLocation W28947720041 @default.
• W2894772004 hasRelatedWork W1506200166 @default.

• next